PI4KIII beta inhibitor 3|cas:1245319-54-3|西域试剂

PI4KIII beta inhibitor 3,99.44%

产品编号：Bellancom-15679| CAS NO：1245319-54-3| 分子式：C₂₂H₂₂N₈OS| 分子量：446.53

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	价格	库存与货期
Bellancom-15679	￥2480.00	杭州北京（现货）
Bellancom-15679	￥3720.00	杭州北京（现货）
Bellancom-15679	￥6696.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

PI4KIII beta inhibitor 3

产品介绍

PI4KIII beta inhibitor 3 是一种新型高效的 ΡΙ4ΚΙΙΙβ 抑制剂，IC₅₀ 为 5.7 nM。

生物活性

PI4KIII beta inhibitor 3 is a novel and high effective PI4KIIIβ inhibitor with IC₅₀ of 5.7 nM.

体外研究

PI4KIII beta inhibitor 3 is a PI4KIII inhibitor extracted from patent WO/2013034738 A1, the compound of formula 3, has an IC₅₀ of 5.7 nM. PI4KIII beta inhibitor 3 exerts significant immunosuppressive activity, with IC₅₀ value of 3 nM in the mixed lymphocyte reaction (MLR) assay. PI4KIII beta inhibitor 3 inhibits IL2 and IFNy secretion with IC₅₀ values of less than InM in each case. Thus, PI4KIII beta inhibitor 3 is shown to be as effective at inhibiting IL2 and IFNy secretion as conventional immunosuppressants such as cyclosporine A. IC₅₀ on IFNy and IL-2 release of Cyclosporine A are 2nM and less than 1 nM respectively.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究

PI4KIII beta inhibitor 3 (40 mg/kg per day, n=12) is able to delay the onset of arthritic symptoms and also to decrease symptom severity in a preventive model of arthritis compared to a vehicle control (MC 1%, n=12). PI4KIII beta inhibitor 3 reduces the anti-CII IgG titre and histological scores in the collagen-induced arthritis mouse model. Oral administration of PI4KIII beta inhibitor 3 results in prolonged graft survival in 3 out of 6 grafts in each group at day 30. Several grafts continued beating after withdrawal of the treatment (up to 60 days), indicating the induction of a certain type of graft tolerance. To evaluate the operational tolerance phenotype, animals with functional graft at day 60 are challenged with a second graft from the same donor strain or from a third party. No treatment is applied. The second grafts from the third party are rejected at day 8 (n=2) whereas second grafts from the same donor strain are functional for more than 90 days (n=2).

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

性状

Solid

溶解性数据

In Vitro:

DMSO : 20 mg/mL (44.79 mM; Need ultrasonic)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	2.2395 mL	11.1975 mL	22.3949 mL
5 mM	0.4479 mL	2.2395 mL	4.4790 mL
10 mM	0.2239 mL	1.1197 mL	2.2395 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式